Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

REVENUES (Tables)

REVENUES (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	December 31,
	2019		2018		2017
Product sales:
Gross product sales	$	53,082	$	16,953	$	—
Discounts and allowances		(9,310)		(3,006)		—
Product sales, net	$	43,772	$	13,947	$	—

Revenues from collaborations:
License revenues		8,696	$	30,562		250
Development milestones		5,500		—		4,234
Research and development services and others		1,320		—		—
Total revenues from collaborations		15,516		30,562		4,484
Total revenues	$	59,288	$	44,509	$	4,484

Customer revenues (as a percentage of gross revenues)

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our gross revenues (as a percentage of gross revenues):


	December 31,
	2019		2018		2017
ASD Healthcare and Oncology Supply		37%		17%		—
McKesson Specialty Care Distribution Corporation		30%		11%		—
Kissei		—		69%		—
BerGenBio		—		—		74%

Schedule of product revenue allowances and discounts

The following tables summarize activity in each of the product revenue allowances and discounts during the year ended December 31, 2019 (in thousands):


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2019	$	623	$	843	$	170	$	1,636
Provision related to current period sales		5,170		2,864		99		8,133
Credit or payments made during the period		(4,500)		(1,906)		(31)		(6,437)
Balance at December 31, 2019	$	1,293	$	1,801	$	238	$	3,332


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2018	$	—	$	—	$	—	$	—
Provision related to current period sales		1,484		1,068		170		2,722
Credit or payments made during the period		(861)		(225)		—		(1,086)
Balance at December 31, 2018	$	623	$	843	$	170	$	1,636